Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: strong growth in blockbuster ranks in 2022; Lilly’s donanemab slow cognitive decline; FDA approves first RSV vaccine; Pfizer anticipates revenue bolus from vaccines; and Astellas buys into ophthalmology.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 5 May 2023, including: strong growth in blockbuster ranks in 2022; Eli Lilly and Company’s donanemab slow cognitive decline; FDA approves first RSV vaccine; Pfizer Inc. anticipates revenue bolus from vaccines; and Astellas Pharma, Inc. buys into ophthalmology.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Top-Selling Drugs 2022: Strong Growth In Blockbuster Ranks" - Scrip, 1 May, 2023.)
(Also see "Lilly’s Donanemab Slows Cognitive Decline; FDA Filing Imminent" - Scrip, 3 May, 2023.)
(Also see "GSK’s Arexvy Is First RSV Vaccine Approved By FDA, But A Second Is Poised To Follow" - Scrip, 3 May, 2023.)
(Also see "Pfizer Anticipates A 'Bolus Of Revenue' From RSV, Prevnar 20 Launches This Year" - Scrip, 2 May, 2023.)
(Also see "Astellas Paying $5.9bn For Iveric To Boost Ophthalmology Presence" - Scrip, 1 May, 2023.)